These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 24737690)

  • 1. Chromosome 17/17q gain and unaltered profiles in high resolution array-CGH are prognostically informative in neuroblastoma.
    Theissen J; Oberthuer A; Hombach A; Volland R; Hertwig F; Fischer M; Spitz R; Zapatka M; Brors B; Ortmann M; Simon T; Hero B; Berthold F
    Genes Chromosomes Cancer; 2014 Aug; 53(8):639-49. PubMed ID: 24737690
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gain of distal chromosome arm 17q is not associated with poor prognosis in neuroblastoma.
    Spitz R; Hero B; Ernestus K; Berthold F
    Clin Cancer Res; 2003 Oct; 9(13):4835-40. PubMed ID: 14581355
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Distal chromosome 17 gains in neuroblastomas detected by comparative genomic hybridization (CGH) are associated with a poor clinical outcome.
    Brinkschmidt C; Christiansen H; Terpe HJ; Simon R; Lampert F; Boecker W; Dockhorn-Dworniczak B
    Med Pediatr Oncol; 2001 Jan; 36(1):11-3. PubMed ID: 11464859
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oligonucleotide array-based comparative genomic hybridization (aCGH) of 90 neuroblastomas reveals aberration patterns closely associated with relapse pattern and outcome.
    Spitz R; Oberthuer A; Zapatka M; Brors B; Hero B; Ernestus K; Oestreich J; Fischer M; Simon T; Berthold F
    Genes Chromosomes Cancer; 2006 Dec; 45(12):1130-42. PubMed ID: 16958102
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Numerical and structural aberrations in advanced neuroblastoma tumours by CGH analysis; survival correlates with chromosome 17 status.
    Cunsolo CL; Bicocchi MP; Petti AR; Tonini GP
    Br J Cancer; 2000 Nov; 83(10):1295-300. PubMed ID: 11044353
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 17q gain in neuroblastoma predicts adverse clinical outcome. U.K. Cancer Cytogenetics Group and the U.K. Children's Cancer Study Group.
    Bown N; Lastowska M; Cotterill S; O'Neill S; Ellershaw C; Roberts P; Lewis I; Pearson AD;
    Med Pediatr Oncol; 2001 Jan; 36(1):14-9. PubMed ID: 11464868
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification and characterization of DNA imbalances in neuroblastoma by high-resolution oligonucleotide array comparative genomic hybridization.
    Scaruffi P; Coco S; Cifuentes F; Albino D; Nair M; Defferrari R; Mazzocco K; Tonini GP
    Cancer Genet Cytogenet; 2007 Aug; 177(1):20-9. PubMed ID: 17693187
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oligonucleotide microarray analysis of gene expression in neuroblastoma displaying loss of chromosome 11q.
    McArdle L; McDermott M; Purcell R; Grehan D; O'Meara A; Breatnach F; Catchpoole D; Culhane AC; Jeffery I; Gallagher WM; Stallings RL
    Carcinogenesis; 2004 Sep; 25(9):1599-609. PubMed ID: 15090470
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gain of chromosome 17 is the most frequent abnormality detected in neuroblastoma by comparative genomic hybridization.
    Plantaz D; Mohapatra G; Matthay KK; Pellarin M; Seeger RC; Feuerstein BG
    Am J Pathol; 1997 Jan; 150(1):81-9. PubMed ID: 9006325
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gain of chromosome arm 17q and adverse outcome in patients with neuroblastoma.
    Bown N; Cotterill S; Lastowska M; O'Neill S; Pearson AD; Plantaz D; Meddeb M; Danglot G; Brinkschmidt C; Christiansen H; Laureys G; Speleman F; Nicholson J; Bernheim A; Betts DR; Vandesompele J; Van Roy N
    N Engl J Med; 1999 Jun; 340(25):1954-61. PubMed ID: 10379019
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of chromosome breakpoints in neuroblastoma at sub-kilobase resolution using fine-tiling oligonucleotide array CGH.
    Selzer RR; Richmond TA; Pofahl NJ; Green RD; Eis PS; Nair P; Brothman AR; Stallings RL
    Genes Chromosomes Cancer; 2005 Nov; 44(3):305-19. PubMed ID: 16075461
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Loss in chromosome 11q identifies tumors with increased risk for metastatic relapses in localized and 4S neuroblastoma.
    Spitz R; Hero B; Simon T; Berthold F
    Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3368-73. PubMed ID: 16740759
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gain of chromosome arm 17q is associated with unfavourable prognosis in neuroblastoma, but does not involve mutations in the somatostatin receptor 2(SSTR2) gene at 17q24.
    Abel F; Ejeskär K; Kogner P; Martinsson T
    Br J Cancer; 1999 Dec; 81(8):1402-9. PubMed ID: 10604740
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of candidate genes involved in neuroblastoma progression by combining genomic and expression microarrays with survival data.
    Łastowska M; Viprey V; Santibanez-Koref M; Wappler I; Peters H; Cullinane C; Roberts P; Hall AG; Tweddle DA; Pearson AD; Lewis I; Burchill SA; Jackson MS
    Oncogene; 2007 Nov; 26(53):7432-44. PubMed ID: 17533364
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Estimation of copy number aberrations: Comparison of exome sequencing data with SNP microarrays identifies homozygous deletions of 19q13.2 and CIC in neuroblastoma.
    Fransson S; Östensson M; Djos A; Javanmardi N; Kogner P; Martinsson T
    Int J Oncol; 2016 Mar; 48(3):1103-16. PubMed ID: 26794043
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Presence of 1q gain and absence of 7p gain are new predictors of local or metastatic relapse in localized resectable neuroblastoma.
    Pezzolo A; Rossi E; Gimelli S; Parodi F; Negri F; Conte M; Pistorio A; Sementa A; Pistoia V; Zuffardi O; Gambini C
    Neuro Oncol; 2009 Apr; 11(2):192-200. PubMed ID: 18923191
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Determination of 17q gain in patients with neuroblastoma by analysis of circulating DNA.
    Combaret V; Bréjon S; Iacono I; Schleiermacher G; Pierron G; Ribeiro A; Bergeron C; Marabelle A; Puisieux A
    Pediatr Blood Cancer; 2011 May; 56(5):757-61. PubMed ID: 21370407
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Breakpoint position on 17q identifies the most aggressive neuroblastoma tumors.
    Łastowska M; Cotterill S; Bown N; Cullinane C; Variend S; Lunec J; Strachan T; Pearson AD; Jackson MS
    Genes Chromosomes Cancer; 2002 Aug; 34(4):428-36. PubMed ID: 12112532
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multicentre analysis of patterns of DNA gains and losses in 204 neuroblastoma tumors: how many genetic subgroups are there?
    Vandesompele J; Speleman F; Van Roy N; Laureys G; Brinskchmidt C; Christiansen H; Lampert F; Lastowska M; Bown N; Pearson A; Nicholson JC; Ross F; Combaret V; Delattre O; Feuerstein BG; Plantaz D
    Med Pediatr Oncol; 2001 Jan; 36(1):5-10. PubMed ID: 11464905
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Deletions in chromosome arms 3p and 11q are new prognostic markers in localized and 4s neuroblastoma.
    Spitz R; Hero B; Ernestus K; Berthold F
    Clin Cancer Res; 2003 Jan; 9(1):52-8. PubMed ID: 12538451
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.